Greenwich LifeSciences Provides Year End Update
Greenwich LifeSciences, Inc. GLSI (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today …